Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.
Meredith McKean, Matthew H. Carabasi,Mark N. Stein,Michael Thomas Schweizer,Jason J. Luke, Vivek Narayan, Rahul Atul Parikh,Russell Kent Pachynski,Jingsong Zhang,Vijay Gopal Reddy Peddareddigari, James Winnberg,Amy Roberts,Jamie Rosen,Pam Hufner,Whitney Gladney, Thomas J. Fountaine,Karen Chagin JOURNAL OF CLINICAL ONCOLOGY（2022）
AI 理解论文
溯源树
样例
